상세 보기
자료 필터
자료유형
발행연도
2008 ~ 2025
2008 2025
키워드
언어
전체 56건 중 21번부터 30번까지의 결과를 표시합니다.
2020
Article
Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
- Cho, B. C. ;
- Lee, K. H. ;
- Cho, E. K. ;
- Kim, D-W. ;
- Lee, J-S. ;
- 외 15명
- 2020-09
- Annals of Oncology
- ELSEVIER
Article
PHMG (polyhexamethylene guanidine) 흡입독성참고치 산출을 통한 가습기살균제 노출등급 분류 및 특성
- 2020-06
- 한국환경보건학회지
- 한국환경보건학회
Article
A phase II trial of genexol-PM and doxorubicin in patients with advanced Her-2 negative breast cancer
- Cho, Eun Kyung ;
- Yun, Hyo Yeon ;
- Kim, Yun Yeong ;
- Jeon, Yong Soon ;
- Park, Heungkyu
- 2020-02
- Cancer Research
- AMER ASSOC CANCER RESEARCH
Article
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- Ramalingam, S. S. ;
- Vansteenkiste, J. ;
- Planchard, D. ;
- Cho, B. C. ;
- Gray, J. E. ;
- ... Cho, Eun Kyung ;
- 외 180명
- 2020-01
- New England Journal of Medicine
- MASSACHUSETTS MEDICAL SOC
Article
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients
- Scagliotti, Giorgio ;
- Moro-Sibilot, Denis ;
- Kollmeier, Jens ;
- Favaretto, Adolfo ;
- Cho, Eun Kyung ;
- 외 14명
- 2020-01
- Journal of Thoracic Oncology
- ELSEVIER SCIENCE INC
2019
Article
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
- Park Y.H. ;
- Kim T.-Y. ;
- Kim G.M. ;
- Kang S.Y. ;
- Park I.H. ;
- ... Cho E.K. ;
- 외 66명
- 2019-12
- The Lancet Oncology
- ELSEVIER SCIENCE INC
Article
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
- Ahn, Myung-Ju ;
- Han, Ji-Youn ;
- Lee, Ki Hyeong ;
- Kim, Sang-We ;
- Kim, Dong-Wan ;
- ... Cho, Eun Kyung ;
- 외 15명
- 2019-12
- The Lancet Oncology
- ELSEVIER SCIENCE INC
Article
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
- Gray, Jhanelle E. ;
- Okamoto, Isamu ;
- Sriuranpong, Virote ;
- Vansteenkiste, Johan ;
- Imamura, Fumio ;
- ... Cho, Eun Kyung ;
- 외 16명
- 2019-11-15
- Clinical Cancer Research
- AMER ASSOC CANCER RESEARCH
Article
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- Paz-Ares, Luis ;
- Dvorkin, Mikhail ;
- Chen, Yuanbin ;
- Reinmuth, Niels ;
- Hotta, Katsuyuki ;
- ... Cho, Eun Kyung ;
- 외 240명
- 2019-11
- The Lancet
- ELSEVIER SCIENCE INC
Article
Efficacy and safety of first-line durvalumab (D) +/- tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
- Cho, B. C. ;
- Lee, K. H. ;
- Ahn, M-J. ;
- Geater, S. Lucien ;
- Ngoc, T. V. ;
- ... Cho, E. K. ;
- 외 12명
- 2019-11
- Annals of Oncology
- OXFORD UNIV PRESS